Skip to main content
Premium Trial:

Request an Annual Quote

Cellular Dynamics, AstraZeneca Ink Stem Cell Partnership

NEW YORK (GenomeWeb News) – Cellular Dynamics today said that it will collaborate with AstraZeneca on developing new human induced pluripotent stem cells for therapeutic discovery screening applications.

Cellular Dynamics said that under the "Center of Excellence" agreement AstraZeneca will use the firm's iCell and MyCell products for iPSC reprogramming and differentiation, and the firms will collaborate on the development of one or more novel cell types. Specifically, Cellular Dynamics said that AstraZeneca will use the MyCell technology to genetically engineer and manufacture cells from specific patient groups for use as in vitro disease models.

Cellular Dynamics CEO Bob Palay noted that the deal with AstraZeneca is the firm's third Center of Excellence agreement with a global pharmaceutical company.

Further terms of the alliance were not disclosed.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.